![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Phase II trial of pirarubicin in the treatment of advanced bladder cancer
Doxorubicin is one of the standard drugs in the chemotherapy of advanced urothelial tumors. Pirarubicin, a new anthracycline, turned out to be equally active and less toxic than its parent compound in preclini...
-
Article
Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer
Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor m...
-
Article
Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer
Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor mo...
-
Article
Open AccessPrognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progressi...
-
Article
Open AccessA phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colo...
-
Article
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
Objective: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy...
-
Article
Open AccessThe risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based chemotherapy, to compare this risk to that of a matched contr...
-
Article
Réflexions sur l’organisation de l’oncogériatrie et rôle des réseaux
Le réseau d’oncogériatrie devra comprendre toutes les personnes et toutes les structures qui gèrent la prise en charge clinique de la personne âgée atteinte de cancer à toutes les étapes de la maladie. Les out...
-
Article
Quelle évaluation gérontologique faut-il utiliser pour les essais multicentriques?
Peu de personnes âgées atteintes de cancer sont incluses dans des essais cliniques. Ainsi, la connaissance sur l’efficacité et la tolérance des traitements est-elle médiocre dans cette population de patients. ...
-
Article
Motesanib difosfato nel cancro tiroideo differenziato progressivo
PREMESSE: L’espressione del vascular endothelial growth factor (VEGF) è tipica dei carcinomi tiroidei differenziati ed è associata ad un comportamento aggressivo e ad una evoluzione sfavorevole. Il motesanib difo...